Thursday 4 September 2008

Cytokinetics Announces Clinical Trials Data Relating To Ispinesib To Be Presented At The 2008 ASCO Breast Cancer Symposium

�Cytokinetics, Incorporated (NASDAQ: CYTK) announced that data from an ongoing Phase I/II clinical trial of ispinesib are scheduled to be presented as a bill sticker presentation at the 2008 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium, to be held September 57, 2008 at the Hilton Washington in Washington, DC.


In June 2008, as part of a bill poster session at the ASCO Annual Meeting, Cytokinetics proclaimed interim data from the Phase I portion of its on-going Phase I/II clinical trial of ispinesib, a novel kinesin spindle protein (KSP) inhibitor, administered as monotherapy as a first-line treatment in chemotherapy-na�ve patients with locally advanced or metastatic breast cancer. The authors concluded that preliminary data suggest that ispinesib is well-tolerated when dosed on days 1 and 15 every 28 days at doses up to 12 mg/m2. Results from extra patients enrolled in the ongoing Phase I, dose-escalation portion of this clinical trial are scheduled to be presented the 2008 ASCO Breast Cancer Symposium.

Poster Presentation at ASCO Breast Cancer Symposium


Abstract #192: "A Phase I-II Trial of Ispinesib, a Kinesin Spindle Protein (KSP) Inhibitor, Dosed Every Two Weeks in Patients (pts) with Locally Advanced (LA) or Metastatic Breast Cancer (MBC) Previously Untreated with Chemotherapy (CT) for Metastatic Disease or Recurrence." (Poster Presentation on Friday, September 5, 2008, during the General Poster Session, 5:30 pm - 6:45 pm Eastern Time). The poster testament be ground in the Exhibit Hall at post-horse board #A50 and presented by Henry Gomez, MD from Instituto Nacional de Enfermedades Neoplasicas (INEN) in Lima, Peru.

About Cytokinetics


Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that may handle areas of significant unmet clinical inevitably. Cytokinetics' cardiovascular disease programme is focused to cardiac myosin, a motor protein essential to cardiac muscle contraction. Cytokinetics' lead compound from this program, CK-1827452, a novel small molecule cardiac myosin activator, entered Phase II clinical trials for the treatment of heart failure in 2007. Under a strategic alignment established in 2006, Cytokinetics and Amgen Inc. ar performing joint research focused on identifying and characterizing activators of cardiac myosin as patronage and follow-on potential do drugs candidates to CK-1827452. Amgen has obtained an option for an exclusive license to develop and commercialise CK-1827452, topic to Cytokinetics' development and commercial participation rights. Cytokinetics' cancer curriculum is focussed on mitotic kinesins, a family of motor proteins essential to cell division. Under a strategic alignment established in 2001, Cytokinetics and GlaxoSmithKline (GSK) are conducting inquiry and development activities focused on the potential discourse of genus Cancer. Cytokinetics is developing deuce novel drug candidates that have arisen from this program, ispinesib and SB-743921, each a novel inhibitor of kinesin spindle protein (KSP), a mitotic kinesin. Cytokinetics is sponsoring a Phase I/II clinical run of ispinesib as monotherapy as a first-line discussion in chemotherapy-na�ve patients with locally advanced or metastatic breast cancer. In addition, Cytokinetics is conducting a Phase I/II trial of SB-743921 in patients with non-Hodgkin or Hodgkin lymphomas. GSK has obtained an option for the join development and commercialization of ispinesib and SB-743921. Cytokinetics and GSK are conducting collaborative inquiry activities directed to the mitotic kinesin centromere-associated protein E (CENP-E). GSK-923295, a CENP-E inhibitor, is existence developed under the strategical alliance by GSK; GSK began a Phase I clinical trial run with GSK-923295 in 2007. In April 2008, Cytokinetics announced the selection of a potency drug campaigner directed towards skeletal muscle contractility which may be developed as a voltage treatment for skeletal muscle weakness associated with neuromuscular diseases or other weather. All of these do drugs candidates and potential drug candidates hold arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a composite biological base that plays a rudimentary role inside every human cell. Additional information about Cytokinetics lavatory be obtained at hTTP://www.cytokinetics.com.


This press release contains advanced statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any design or obligation to update these modern statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, merely are non limited to, statements relating to Cytokinetics' research and development programs, including plotted presentations relating to clinical trial results, and the properties and potential benefits of Cytokinetics' drug candidates and electric potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential drop difficulties or delays in the development, testing, regulative approval or production of Cytokinetics' drug candidates that could slow or foreclose clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be declarative of future clinical trials results, affected role enrollment for clinical trials may be difficult or delayed, Cytokinetics' drug candidates may have adverse side effects or inadequate remedial efficacy, the U.S. Food and Drug Administration or foreign regulatory agencies whitethorn delay or limit Cytokinetics' or its partners' ability to carry on clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Cytokinetics may incur out of the blue research and development and other costs or be unable to obtain extra financing necessary to conduct development of its products; standards of care whitethorn change and others may introduce products or alternative therapies for the intervention of indications Cytokinetics' do drugs candidates and potential do drugs candidates whitethorn target; and risks and uncertainties relating to the timing and receipt of payments from Cytokinetics' partners, including milestones and royalties on future potential product sales under its coaction agreements with such partners. For further information regarding these and other risks related to Cytokinetics' patronage, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

Cytokinetics


More info

Monday 25 August 2008

Calif. AG, Family Planning Advocates Say Proposed HHS Rule Would Overturn State Birth Control Law

�California Attorney General Jerry Brown (D) and some family planning advocates on Wednesday said that a draft HHS regulation would prohibit the state from enforcing the state law requiring insurance coverage for birth control to women, the San Francisco Chronicle reports (Egelko, San Francisco Chronicle, 8/21). Also on Wednesday, the Planned Parenthood Action Fund and MoveOn.org Political Action submitted a petition with more than 325,000 signatures urgency HHS Secretary Mike Leavitt to pull back the draft rule from consideration, ABC News reports (Barrett, ABC News, 8/20).

According to the Chronicle, the administration drafted the proposal to implement laws prohibiting recipients of federal cash in hand from penalizing health practitioners who reject to perform abortions or provide abortion referrals (San Francisco Chronicle, 8/21). At the news conference announcing the request, Ellen Golombek, PPAF vice president of external affairs, said the draft regulation "would allow providers to withhold critical health upkeep information without telling their patients." According to ABC News, other advocates illustrious that the draft "muddies the line between miscarriage and contraception, and look at it an opening for health attention providers to more oftentimes refuse to prescribe birth control and other forms of contraception and point of accumulation women's health care options" (ABC News, 8/20).

The leaked draft principle defines abortion as "whatsoever of the various procedures -- including the prescription and governance of whatever drug or the performance of whatever procedure or any other action -- that results in the termination of the life sentence of a human being in utero between conception and natural birth, whether before or after nidation" - a definition of abortion that could include many forms of hormonal contraception and intrauterine devices. (Daily Women's Health Policy Report, 8/11).

Brown in an Aug. 4 letter to Leavitt wrote, "By financially punishing noncompliant states with the personnel casualty of (federal) funding, the regulation would intrude on the government agency of states to reenact and enforce laws that ensure women's access to birth control." California's practice of law, which was passed in 2000 and upheld by the state Supreme Court in 2004, was passed in response to the decision by some indemnity companies to cover male infertility drugs but not oral contraception for women. The legal philosophy exempts church building employees, just the land Supreme Court ruled that the criterion applies to the 52,000 employees of Catholic hospitals and 1,600 employees of Catholic Charities.

The U.S. Supreme Court declined to hear an appeal by Catholic Charities on the California opinion and a similar ruling by the New York Supreme Court. Twenty-five states have torah similar to California's measure, according to the Guttmacher Institute.

If the draft HHS regulation is enacted, it would be a "monster step down a road that volition potentially leave women with a major loss of access to contraceptive methods," Kathy Kneer, CEO of Planned Parenthood Affiliates of California, aforementioned. She added that opponents of the rule volition continue spur members of Congress and federal officials to plosive it from being issued, adding that if they fail they will inquire the succeeding president to repeal the rule (San Francisco Chronicle, 8/21).

Leavitt in an Aug. 7 web log entry said he has ordered the draft regulation to be rewritten with a narrow focus on allowing health care workers to refuse to participate in procedures they receive objectionable. He also aforementioned that HHS is "still contemplating if it will issue a regulation or not. If it does, it testament be direct focused on the shelter of practitioner conscience." However, Leavitt did not say what he meant by "practitioner sense of right and wrong" or the extent to which the protection would allow health care workers to refuse services (Daily Women's Health Policy Report, 8/11).

David Stevens, CEO of the Christian Medical and Dental Associations, said many of the group's 15,000 members have been denied jobs or promotions for refusing to perform abortions or prescribe contraceptives that they believe ar the eq of abortion. "There is an organized effort to force health care professionals to do things that violate their conscience," Stevens said. According to the Chronicle, the proposed ruler is backed by some other religious organizations opposed to abortion, and it is opposed by the American Medical Association, the American College of Obstetricians and Gynecologists and cl members of Congress, including Democratic presidential candidate Sen. Barack Obama (Ill.) (San Francisco Chronicle, 8/21).


Reprinted with tolerant permission from http://www.nationalpartnership.org. You can view the entire Daily Women's Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women's Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company.


� 2008 The Advisory Board Company. All rights reserved.




More info

Friday 15 August 2008

Blobtown: Movie memories revitalize a community

PHOENIXVILLE, Pa. �

There is a man. He carries a can, and inside it is a weird, cerise hunk of goo the size and consistency of a generous bowl of lumpy raspberry Jell-O.


Each summertime, man and can climb into the car and drive to a lowly town on the edge of the Philadelphia suburbs, not far from where Washington played out that bitter, long-ago wintertime in Valley Forge.


The town, Phoenixville, is a plaza of history, too. Fifty years agone, this position was affected by the spotlight. A small production company deuce towns over made a film that no one expected to go anywhere. Instead, it became one of the iconic sci-fi horror flicks of the 1950s and introduced the world to an thespian named Steve McQueen.


In the movie, this happens: A mysterious lump of extraterrestrial gelatin kills a doctor in his home, menaces teenagers in a grocery store, surges toward a crowd of people in a darkened theater and engulfs a diner.


In tangible life, this happens: Each summer, hundreds of locals and folk from as far out as Oregon and Jamaica come to the center of Phoenixville. They visit the house where the doctor "died," stop by the strip mall where the market once stood, eat at the dining compartment on the site where the outlander met its frozen final stage. And, on Phoenixville's main drag, on a warm summer evening, more than 400 of them carry screaming from the like theater, the Colonial, in a joyous re-enactment of the movie's big scene.


The man and the can play starring roles in The Big Weekend and its ocean of science fiction fans and weekend excursioneers. The adult male is Wes Shank, aggregator of picture show memorabilia. The can contains his piece de resistance, the matter that gave rise to all the commotion in the first-class honours degree place.


It is a toy film airplane propeller, nothing more, a clump of silicone polymer manufactured by Union Carbide in West Virginia. But it is also the centerpiece of a story of tourism and entertainment that, a half-century and six manned moon landings later, refuses to go away.


All around the hunk of guck, something unmated unfolds: Because a picture was made long ago, because a town's gotta do what a town's gotta do, a fete has risen. A downtown has amount back. A past has been leveraged - a fictional past, but a past nevertheless.


Once, in 1958, "The Blob" came from beyond the stars and brought expiry to Phoenixville. Today, scarce as out of the blue, it is bringing life.


---


"When you see something that was on film, it takes you into the movie. It's almost care you are a character," says Dave Perillo, an artist from Swarthmore, Pa. He has come to hawk his sci-fi caricatures at "Blobfest," Phoenixville's name for its annual street-fair excursion into the blobosphere.


"These places," Perillo says, "are our fresh historic sites for the ADD generation."



Entertainment can be an unpredictable beast. What appears up on the big screen - some of it, at least - was created in real places. And sometimes, because of the fabrication, those real places begin to change.


In Scotland, an ancient rook has turn a pilgrimage site because part of "Monty Python and the Holy Grail" was filmed there. In Dyersville, Iowa, the baseball game diamond carven from cornfields for "Field of Dreams" draws fans who consider it a real ballpark. Mount Airy, N.C., has taken nisus to work itself feel like Mayberry, the quintessential small ithiel Town from "The Andy Griffith Show." And the browning automatic rifle exterior from "Cheers," erstwhile called the Bull and Finch, has renamed itself; these days, it's "Cheers Beacon Hill."


We live in a ground of big stories, in an years where amusement trumps most everything. So events like Blobfest become natural leisure options at a meter when towns need to stand out, to become on-site motif parks and draw tourer dollars.


And here in the cradle of American independence, where real world history is everywhere, why shouldn't fictional history turn something tangible?


"History, the Liberty Bell, the significance of it gets lost of me," says Ellen Plummer of Portland, Maine. "This," she says, "is more real."


She is walking up Bridge Street in Phoenixville with her boyfriend, Rick Naratil, a native world Health Organization moved away years agone. He remembers, at 5, seeing "The Blob" on TV and thinking, hey - that's the field where I watch Disney movies.


While the diner and other motion-picture photography locations draw gawkers during Blobfest, the Colonial Theater is the epicenter of all things blob. Inside, sci-fi flicks play to enthusiastic audiences, and people at the edges of fame like Kris Yeaworth, son of "Blob" theater director Shorty Yeaworth, discuss the intricacies of filming the movie originally titled "The Molten Meteor."


Outside, the blobbery takes on as many forms as creativity and entrepreneurial apprehension allow.


There is the wooden blob cutout that allows you to poke your head through a gob and make believe you're being swallowed by its spiritual maw. There are the actual fervor truck and the 1950 Ford coupe that McQueen drove in the motion-picture show. Outside the pizza parlour opposite the theater, the proprietors consume created their own creamy, oozy garden pink mass, confined to a garbage bank identification number for the moment.


And there is the parade, lED by a 203% surprisingly, and ironically, authentic.


Modeling one's self after film tin be briary; real history can get lost. But it's hard to find a downside in Phoenixville. The sir Ernst Boris Chain of custody is pretty basic. Theater came punt. Community leveraged blob. Business resurged. Downtown got safer. Everybody's happy.


Even now, almost a decennary into Blobfest, a bemusement remains around the enthusiasm generated by the alien-visitation tale filmed the summertime before Sputnik was launched.


"I take the ride. But do I get it? No," Foote acknowledges. "The volunteers wHO work all year, half of them don't beget it. They say, `Why do they come?'"


Karin Williams, who does PR for the Phoenixville Chamber of Commerce, echoes many along Bridge Street when she assesses the whole occasion: A biotic community identifiable by something strictly pop-cultural isn't a bad thing amid the static of the 21st century.


"It puts our little

Thursday 7 August 2008

Dorn

Dorn   
Artist: Dorn

   Genre(s): 
Metal: Gothic
   Metal: Doom
   Metal: Death,Black
   



Discography:


Suriel   
 Suriel

   Year: 2004   
Tracks: 9


Schatten Der Vergangenheit   
 Schatten Der Vergangenheit

   Year: 2002   
Tracks: 9


Falschheit   
 Falschheit

   Year: 2000   
Tracks: 9




 






Friday 27 June 2008

Angelina Jolie - Jolie Fears Shes Missed Out On Atlas Film With Pitt


ANGELINA JOLIE fears she and partner BRAD PITT have missed their chance to make a movie together - because she got pregnant.

The actress admits the Hollywood couple was in talks to team up for Atlas Shrugged before she learned she was expecting twins.

She tells Entertainment Weekly magazine, "It's been 50 years of people trying to pull a movie together. If it comes together it'd be hard to say no to.

"The people who have the rights are itching to do it. They were itching to do it before, but I got myself in a state!"





See Also

Monday 23 June 2008

Naomi Campbell - Campbells Temper Rages Again


NAOMI CAMPBELL's stint in anger management therapy has reportedly proved unsuccessful after the supermodel was seen shouting in a rage after a night out on Monday (17Jun08).

The embattled star appeared to be in good spirits as she happily posed for photographers following a meal with friends at London's Cipriani restaurant.

But her pleasant demeanour quickly dissipated when she suddenly began shouting and gesturing angrily, before inexplicably hurrying back into the Mayfair eaterie.

An onlooker tells The London Paper, "Suddenly Naomi flipped and started swinging her arms about manically. No one could work out what was wrong with her."

But the catwalk queen's erratic behaviour didn't end there. Moments later, she emerged apparently restrained by three pals, who led her into her car as she seemed to wriggle out of their firm grasp.

The source adds: "She was shouting and screaming as her friends desperately tried to get her into the car. She was ranting incomprehensibly."

The 38-year-old was ordered to attend a two-day anger management course last year (07) after she pled guilty to reckless assault against her maid Ana Scolavino.

Campbell is now facing a possible prison sentence after being charged with allegedly assaulting a police officer following her arrest at London's Heathrow Airport in April (08).





See Also

Monday 16 June 2008

Body art star tastes victory (+pics)

A komodo dragon creation fired Carmel McCormick to success at the New Zealand Body Art Awards judged by Oscar-winning special effects guru Richard Taylor.

McCormick's win on Saturday was her third in the annual competition.

More than 1800 people came to the North Shore Events Centre in Auckland to see 73 of the country's best body artists in action.

Event creative director Mem Bourke said the artists had up to six hours to paint their models in a jungle theme before they were paraded before the judging panel.

The artists were then able to make changes right up to the start of the public showing.

The night was a double success for McCormick, who also placed first-equal in the Hand Painted Body Art section.

In 2007 she won the supreme award by painting two models to look like Lord and Lady Byron.

Bourke said body painting in New Zealand was more popular than ever, with about 350 painters plying their trade around the country.

This year, competitors from South Island and Australia took part for the first time.

The event will be held again in June 2009. 

 





See Also